Intellectual Property
More Intellectual Property Articles
Life Sciences
A Slow-Moving Animal: The 150-year evolution of the law of patentable subject matter
MCC: We just passed the three-year anniversary of the Supreme Court’s ruling in Mayo v. Prometheus. How much of a game-changer is this case? Maslowski: The law tends to be a slow-moving animal, so at this point, it’s still hard to say whether Mayo is a big game-changer. Its impact...
Read MoreLife Sciences
When the Stakes Are Highest: Hard work drives enviable track record in Hatch-Waxman litigation
MCC: Share a little bit with us about your practice at Fish & Richardson and how the firm works with life sciences companies. Singer: Fish has the premier patent litigation practice in the world, handling approximately twice as many patent cases as our nearest competitor. Our life...
Read MoreLife Sciences
Biosimilars: Poised to Turn to Inter Partes Review to Resolve Patent Disputes
On March 6, 2015, the U.S. Food and Drug Administration (FDA) approved the first biosimilar drug in the U.S., Sandoz’s ZarxioTM, to treat cancer patients who are at increased risk for infection. A “biosimilar” is a biological product that is highly similar to an existing FDA‑...
Read More